title: Induction of an altered lipid phenotype by two cancer promoting treatments in rat liver.
abstract: Changes in lipid metabolism have been associated with tumor promotion in rat liver. Similarities and differences of lipid parameters were investigated using the mycotoxin fumonisin B1 (FB1) and the 2-acetylaminofluorene/partial hepatectomy (AAF/PH) treatments as cancer promoters in rat liver. A typical lipid phenotype was observed, including increased membranal phosphatidylethanolamine (PE) and cholesterol content, increased levels of C16:0 and monounsaturated fatty acids in PE and phosphatidylcholine (PC), as well as a decrease in C18:0 and long-chained polyunsaturated fatty acids in the PC fraction. The observed lipid changes, which likely resulted in changes in membrane structure and fluidity, may represent a growth stimulus exerted by the cancer promoters that could provide initiated cells with a selective growth advantage. This study provided insight into complex lipid profiles induced by two different cancer promoting treatments and their potential role in the development of hepatocyte nodules, which can be used to identify targets for the development of chemopreventive strategies against cancer promotion in the liver.
authors: Diabetes Discovery Platform, South African Medical Research Council, PO Box 19070, Tygerberg, South Africa. Electronic address: sylvia.riedel@mrc.ac.za.
authors: S
authors: S
authors: Riedel
authors: Institute of Biomedical and Microbial Biotechnology, Cape Peninsula University of Technology, PO Box 1906, Bellville 7535, South Africa.
authors: S
authors: S
authors: Abel
authors: Biostatistics Unit, South African Medical Research Council, PO Box 19070, Tygerberg, South Africa.
authors: S
authors: S
authors: Swanevelder
authors: Institute of Biomedical and Microbial Biotechnology, Cape Peninsula University of Technology, PO Box 1906, Bellville 7535, South Africa; Department of Biochemistry, Stellenbosch University, Private Bag X1, Matieland 7602, South Africa.
authors: W C A
authors: WC
authors: Gelderblom
mesh_terms: D015073:2-Acetylaminofluorene / Q000008:administration & dosage* / Q000633:toxicity; D000818:Animals; D002784:Cholesterol / Q000378:metabolism; D005227:Fatty Acids; D005229:Fatty Acids, Monounsaturated / Q000378:metabolism; D005231:Fatty Acids, Unsaturated / Q000378:metabolism; D037341:Fumonisins / Q000008:administration & dosage* / Q000633:toxicity; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism; D050356:Lipid Metabolism / Q000187:drug effects*; D008099:Liver / Q000378:metabolism; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced / Q000378:metabolism*; D008297:Male; D010641:Phenotype; D010713:Phosphatidylcholines / Q000378:metabolism; D010714:Phosphatidylethanolamines / Q000378:metabolism; D051381:Rats; D011916:Rats, Inbred F344
chemical_list: D005227:Fatty Acids; D005229:Fatty Acids, Monounsaturated; D005231:Fatty Acids, Unsaturated; D037341:Fumonisins; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; C483858:phosphatidylethanolamine; C056933:fumonisin B1; D002784:Cholesterol; D015073:2-Acetylaminofluorene
keywords: 2-Acetylaminofluorene; Cancer promotion; Fatty acids; Fumonisins; Hepatocyte nodules; Rats